SI-BONE, Inc. Announces France’s National Healthcare System Establishes Exclusive Positive Coverage for the Triangular iFuse Implant System® for MIS SI Joint Fusion
8/27/18: Exclusive coverage based on published clinical evidence begins September 6, 2018 and extends for 5 years.
SI-BONE, Inc. Announces 23 Commercial Health Insurance Plans Now “Exclusively” Cover Triangular iFuse Implant System® Based on Published Clinical Evidence
8/7/18: "Payers continually tell us that long-term outcomes data from well-designed, well-executed randomized controlled trials are critically important when determining coverage for new procedures or technologies," said Jeffrey Dunn, President, CEO and Chairman of SI-BONE.
SI-BONE, Inc. Announces FDA Clearance and Full U.S. Commercial Launch of the iFuse-3D™ Implant, a Patented, 3D-Printed Next Generation Member of the iFuse Implant System®
About SI Joint Dysfunction The SI joint has been attributed as a source of pain in 15-30 percent of patients with chronic low back pain2-5, and in up to 43 percent of patients with new onset or persistent...